Economic and Clinical Burden Associated with Respiratory Syncytial Virus (RSV) and Expected Impact of Universal Immunization with Nirsevimab Among All Infants in Their First Rsv Season Against Standard of Care in Italy

Speaker(s)

Bini C1, Marcellusi A2, Muzii B3, Soudani S4, Kieffer A5, Beuvelet M6, Mennini FS2
1Economic Evaluation and HTA (EEHTA-CEIS), DEF Department, Faculty of Economics, University of Rome 'Tor Vergata', Roma, RM, Italy, 2Economic Evaluation and HTA (EEHTA-CEIS), DEF Department, Faculty of Economics, University of Rome 'Tor Vergata', Rome, Italy, 3Sanofi, Rome, Italy, 4Sanofi, Lyon, 69, France, 5Sanofi, Lyon, France, 6Sanofi Pasteur Global, Lyon, France

Presentation Documents

OBJECTIVES: To describe the seasonal RSV burden in Italy in terms of health events and associated costs considering the current prophylaxis strategy with palivizumab targeting only high-risk infants (preterm≤ 35 weeks’ gestational age or with congenital heart or chronic lung disease, representing 4.4% of a birth cohort). A cost-consequences analysis was also conducted to evaluate the potential benefits of a new prophylaxis strategy targeting all infants with nirsevimab.

METHODS: A static decision analytic model previously used in US was employed to evaluate the health and cost outcomes associated with nirsevimab versus standard of care for the prevention of RSV medically attended lower respiratory tract infection (RSV-MA-LRTIs). Monthly probabilities of RSV infections, health events, mortality and complications associated with RSV infections were obtained from the literature. Costs associated with each event were obtained using the available literature and through a real-world data analysis of National Hospital Discharge Records. Nirsevimab efficacy was derived from a prespecified pooled analysis of the phase IIb and MELODY clinical trials and for palivizumab from a systematic literature review. Currently, the coverage rate for palivizumab among eligible infants is estimated at 40%; in the cost-consequences analysis, a coverage rate of 60% was assumed for nirsevimab in all infants.

RESULTS: For 2024-2025 RSV season, the model estimated 223,639 RSV-MA-LRTIs, 15,760 associated complications and 19 deaths – corresponding to an economic burden of approximately €52.7 million related to managing the RSV-MA-LRTIs, €11.4 million associated to complications and €3.5 million in lost productivity due to deaths. Universal immunization of all infants with nirsevimab is expected to prevent 103,398 RSV-MA-LRTI, 7,226 complications and 7 deaths due to RSV infections, corresponding to an economic saving of about €24.1 million, €5.2 million and €1.4 million respectively.

CONCLUSIONS: Nirsevimab as a new prophylaxis strategy protecting all infants could reduce the clinical and economic burden of RSV in Italy.

Code

EE696

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Pediatrics